UNSPSC 51286500: Antibacterial pyrans

This classification denotes antibacterials that have five carbon atoms, one oxygen atom, and two double bonds, substances also sometimes called oxines.

UNSPSC 51286500 Antibacterial pyrans, a Class code, does not align with the state and local procurement activity tagged under it. The recent opportunities on file show acquisition of naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, medical and first aid supplies for fire rescue operations, and generic pharmaceuticals and over-the-counter products through cooperative purchasing — none of which are antibacterial pyrans. The code appears to capture pharmaceutical and medical supply procurement in practice, though the tagged solicitations span a broader scope of health-related products and services than the narrow chemical compound the code nominally describes.

State and local buying under this code spans county health departments, state health and human services agencies, municipal fire and rescue divisions, and multistate cooperative purchasing alliances. Issuing bodies include Seminole County, Florida; the Texas Health and Human Services Commission; the City of Tampa; and the Minnesota Department of Administration (MMCAP), which coordinates purchasing across multiple states including Oregon. Recent activity appears concentrated in the South and Midwest, with single opportunities posted from Florida, Texas, and Minnesota in the first half of 2026. Representative recent solicitations include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually (IFB60459723LAS, response due July 26, 2023, though the posting date shown is June 30, 2026), the City of Tampa's IFB for medical and first aid supplies for the Fire Department Rescue Division estimated at $700,000 (26P00145, due March 13, 2026, with a Small Local Business Enterprise sheltered-market designation and 5 percent bid discount), and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products with responses due March 26, 2026. The Texas HHS Commission also issued an RFI on direct-to-manufacturer prescription programs (HHS0017013, response due April 3, 2026) to gather vendor capabilities before formal competitive solicitation.